BIOTECH ASSISTANT / FIELD NOTES

CSPC initiates first Chinese center for SYS6055-003 in vivo CAR-T trial

Company / institutional announcement · CSPC Pharmaceutical Group

Source published: 2026-11-06 · Event / reporting date: 2026-11-06

Site published: 2026-11-07 · Updated: 2026-11-07

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

CSPC announced initiation of the first Chinese center for SYS6055-003, a Phase 1/2 trial in relapsed or refractory B-cell non-Hodgkin lymphoma. SYS6055 uses lentiviral vectors to generate CD19-targeting CAR-T cells in vivo. The company said recruitment and screening are underway following October clinical-trial authorization. Center initiation does not establish patient dosing, efficacy, or marketing approval.

Why it may matter

Analysis: The trial may provide human evidence for lentiviral in vivo CAR-T, with clinical operations, biodistribution, and long-term safety monitoring central to execution.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Edited by the Biotech Assistant content team and reviewed by an authorized publisher. Editorial standards and corrections

In Vivo Cell Engineering & Gene Editing China Clinical CROs & IIT Partners

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

Pharmaron Immorna Strand Therapeutics Orna Therapeutics Orbital Therapeutics

Explore field companies →Explore literature →

Related updates

2026-11-06Azalea Therapeutics / GlobeNewswire

Azalea reports durable tumor control with in vivo TRAC-CAR engineering in mice

Azalea reported SITC preclinical findings for its dual-vector in vivo CAR-T platform, combining targeted CRISPR-Cas9 delivery with AAV-mediated CAR insertion at the TRAC locus. The company described leukemia clearance and protection after tumor rechallenge in selected mouse groups, plus dual-antigen and armored designs. These are animal findings, not evidence of efficacy or safety in patients.

In Vivo Cell Engineering & Gene Editing Ask AI ↗

2026-11-05Intellia Therapeutics

Intellia reports completed MAGNITUDE-2 enrollment and advances launch preparations

Intellia's third-quarter update reports completed enrollment in the Phase 3 MAGNITUDE-2 trial of nexiguran ziclumeran for hereditary ATTR amyloidosis with polyneuropathy, exceeding the target of 60 randomized patients. The company also described commercial preparations for lonvoguran ziclumeran in hereditary angioedema, ahead of its March 10, 2027 FDA target action date. Approval remains pending.

In Vivo Cell Engineering & Gene Editing Ask AI ↗

2026-11-05Precision BioSciences / Business Wire

Safety board supports further PBGENE-DMD dosing after first patient's eight-week review

Precision BioSciences said an independent safety board endorsed additional dosing in the Phase 1/2 FUNCTION-DMD study after reviewing the first PBGENE-DMD recipient's eight-week observation period. No serious adverse events or adverse events of special interest were reported in that patient. The AAV-delivered gene-editing program remains investigational; this single-patient review does not establish efficacy or broader safety.

Companies mentionedPrecision BioSciences ↗

In Vivo Cell Engineering & Gene Editing Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗